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Prostate cancer is second only to lung cancer as the leading cause
of death and is the most prevalent cancer amongst men in the USA
and Europe and accounts for about a third of all cancers diagnosed
each year in men. In the UK, the incidence of prostate cancer has
almost doubled over the last 30 years. Similarly, in 1998, it was
estimated that more than 334 500 cases were diagnosed and more
than 41 800 men died of the disease in the USA (Dijkman and
Debruyne, 1996). The prostate gland is under the influence of
androgens and often becomes enlarged in older men. It has clearly
been demonstrated that prostate cancers are androgen-dependent
and that withdrawal of androgen supply produced favourable
response in patients with adenocarcinoma of the prostate
(Saunders, 1963; Rosenberg and Eschenbach, 1990). Localized
prostate cancer is curable and although the metastatic form of the
disease is difficult to manage, endocrine therapy does reduce the
death rate from the disease and is first-line treatment for all
patients. In the testis and adrenals, 17a-hydroxylase/C17,20-lyase
converts the C21 steroid precursors to the corresponding C19 andro-
gens. Testosterone (T) is further converted to the more potent
androgen dihydrotestosterone (DHT) by 5a-reductase in the
prostate (Bruchovsky and Wilson, 1968). Both T and DHT stimu-
late prostatic growth, although DHT plays a much more important
role than T in the organogenesis and homeostasis of the prostate
(Wilson, 1996). Current endocrine therapies such as orchidectomy
and luteinizing hormone releasing hormone (LHRH) agonists
result in reduced androgen production by the testis and are useful
in the early stages of prostate cancer. However, these treatment
options fail to alter androgen production by the adrenals that may
contribute androgen precursors to the prostate. The addition of
flutamide, an anti-androgen to inhibit the action of androgens on
the prostate, is only partially effective as the disease frequently
progresses due to mutations in the androgen receptor, which can
utilize flutamide as an agonist. It would appear that total androgen
blockade can be therapeutically more effective than conventional
androgen ablation therapy (Labrie et al, 1983). However, more
effective therapeutic strategies for combating prostate cancer are
needed. This may be achieved through dual inhibition of 17a-
hydroxylase/C17,20-lyase and 5a-reductase (Li et al, 1992; Klus
et al, 1996). Several derivatives of oestrogens, progestins and
androgens which diminish androgen levels by inhibiting key
enzymes in the androgen synthesis cascade have been described
(Ayub and Levell 1987; Angelastro et al, 1989; Nakajin et al,
1989; Jarman et al, 1990; Njar and Brodie, 1999). Currently,
ketoconazole, an active imidazole fungicide, is the only 17a-
hydroxylase/C17,20-lyase inhibitor that is used clinically to reduce
testosterone biosynthesis in the treatment of patients with
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weights to a similar extent as castration or flutamide treatment. L-39 also significantly (P < 0.01) reduced serum PSA levels by more than
80% in the mice bearing human prostate cancer xenografts. Pharmacokinetic studies were also conducted in male Balb/c mice. After
subcutaneous administration of a single bolus dose, L-39 was rapidly absorbed into the systemic circulation. Peak plasma levels occurred at
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demonstrate that L-39 is a potent inhibitor of androgen synthesis and is effective in reducing the growth of human prostate cancer xenografts
in nude mice. Although improvements in the bioavailability are necessary, L-39 is a potential lead compound with this profile as an inhibitor of
prostate cancer growth. © 2000 Cancer Research Campaign
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advanced prostate cancer (Small et al, 1997). However, ketocona-
zole is not very potent and it inhibits several other steroidogenic
enzymes and has a number of significant side-effects (Ayub and
Levell, 1987; Trachtenberg, 1984). 5a-Reductase occurs in two
isoforms namely, type I and type II. The type II isoenzyme is the
predominant form in the human prostate. Finasteride, which was
recently approved for the treatment of benign prostatic hyper-
trophy (BPH), is a more potent inhibitor of the type II than the type
I isoform (Cunningham and Hirshkowitz, 1995). However, finas-
teride is only effective against benign prostatic hypertrophy (BPH)
in patients with minimal disease and although the compound
reduced DHT levels, it also increased serum T levels (Peters and
Sorkin, 1993).
We have previously reported the synthesis and testing of several
steroidal inhibitors of 17a-hydroxylase/C17,20-lyase and 5a-reduc-
tase (Li et al, 1995, 1996; Ling et al, 1997; Njar et al, 1998). These
compounds were demonstrated to be effective dual inhibitors of
human testicular 17a-hydroxylase/C17,20-lyase and prostatic
5a-reductase in vitro (Nnane et al, 1998, 1999; Grigoryev et al,
1999). In animal studies, the compounds diminished the levels of
circulating T and DHT in male rat tissues. In LNCaP cell cultures,
several of our novel steroidal compounds including 17-(5¢-isoxa-
zolyl)androsta-4,16-dien-3-one (L-39; Figure 1) inhibited cellular
proliferation and were effective at slowing LNCaP human
prostatic cells grown in male severe combined immunodeficient
(SCID) mice as tumours. L-39 (5 mM) has also been shown to
manifest anti-androgenic activity in cultures of human prostate
cancer cell lines (LNCaP) by preventing the labelled synthetic
androgen R1881 (5 nM) from binding to the androgen receptors
(Long et al, 1999). These compounds, especially L-39, could be
more effective than current therapies in the treatment of prostate
cancer due to their multiple activities. In the present investigation,
we describe the effects of L-39, a novel androstene derivative, in
vitro and on human prostate cancer xenografts in nude mice. We
also evaluated the pharmacokinetic properties of L-39 in male
mice in this investigation.
MATERIALS AND METHODS
Chemical inhibitors and reagents
17-(5¢-Isoxazolyl)androsta-4,16-dien-3-one (L-39) and its D5
hydroxy derivative (L-38) were synthesized in our laboratory
according to procedures described previously (Ling et al, 1997).
Finasteride was a gift from Merck Research Laboratories
(Rahway, NJ, USA) and ketoconazole was purchased from Sigma
Chemical Company (St Louis, MO, USA). [21-3H]-17a-hydroxy-
pregnenolone (13.61 mCi mmol–1) was prepared in our laboratory
as previously described (Njar et al, 1998). [1,2,6,7-3H]-
Testosterone (96.5 Ci mmol–1) and [4-14C]-dihydrotestosterone
(56.5 mCi mmol–1) were obtained from Dupont (Boston, MA,
USA). Silica gel thin layer chromatographic (TLC) plates
(20  ´ 20 cm, w/uv 254, 500 microns, GF) were obtained from
Analtech (Newark, DE, USA). The active [125I]-T coated-tube
radioimmunoassay (RIA) kits and the [125I]-DHT coated tube RIA
kits for quantitative measurement of T and DHT, respectively,
were purchased from DSL Inc. (Webster, TX, USA). All
other reagents were purchased from Sigma Chemical Company
(St Louis, MO, USA).
Preparation of microsomes
Human testes and prostate tissue (from patients with benign
prostatic hyperplasia, BPH) were obtained from Dr James Mohler,
Director, Urologic Oncology, University of North Carolina at
Chapel Hill and stored at –70°C prior to use. Testicular and
prostatic microsomes were prepared as described previously (19).
Briefly, human testis or prostate was washed with saline (0.9%),
blotted dry and weighed. The tissue was minced and homogenized
in a blender with two volumes of sucrose (250 mM). The
homogenates were added to 50-ml plastic centrifuge tubes and
centrifuged at 10 000 g for 30 min. The resulting supernatant was
centrifuged at 109 000 g for 1 h using an ultra-centrifuge. The
microsomal pellet was covered with 2 ml of phosphate buffer
(0.1 M) and stored at –70°C until required for assay. The micro-
somal protein content was determined by the Lowry method
(Lowry et al, 1951).
17a-hydroxylase/C17,20-lyase activity
The measurement of the activity of the human 17a-hydroxylase/
C17,20-lyase in testicular microsomes, in the absence and presence
of inhibitors was performed as described previously (Li et al,
1995). Briefly, the 17a-hydroxylase/C17,20-lyase activity was
determined by measuring the release of [3H]-acetic acid during the
conversion of [21-3H]-17a-hydroxypregnenolone to dehydroepi-
androsterone. The incubations were carried out in a total volume
of 1.01 ml. Sample tubes were supplied with 10 ml of propylene
glycol, 300 000 dpm of [21-3H]-17a-hydroxypregnenolone (13.61
mCi mmol–1) and the indicated inhibitors. The control incubations
were prepared without the addition of the indicated inhibitors.
After evaporation of the ethanolic solution, the following were
added to each tube: 750 ml of 0.1 M sodium phosphate buffer 
(pH 7.4, with 78 mM of dithiothreitol (DTT)) and 50 ml of an
NADPH generating system (phosphate buffer containing 6.5 mM
of NADP+, 71 mM of glucose-6-phosphate, 1.25 IU of glucose-6-
phosphate dehydrogenase). The tubes were pre-incubated for 15
min at 37 °C and the reaction was started by adding 200 ml of
human testicular microsomes (300 mg protein per 200 ml of phos-
phate buffer). The reaction tubes were incubated at 37°C under
oxygen. After 1 h, the tubes were placed in an ice bath and steroids
in the reaction mixture were extracted two times with chloroform
(1 ml). The tubes were allowed to stand at 4°C for 20 min,
centrifuged at 4°C for 15 min at 2000 g and then 0.75 ml of the
aqueous phase of each tube was placed into a fresh tube. To
remove residual steroids, which may remain after the chloroform
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extraction, 0.75 ml of charcoal solution (2.5 g of activated char-
coal per 100 ml of distilled water) was added to each tube and
mixed vigorously. After standing for 30 min, the charcoal was
pelleted by centrifugation at 2000 g for 20 min. Finally, 0.75 ml of
the supernatant was analysed for tritium by liquid scintillation
spectrometry. The reaction conditions were optimized with
0.1–6.0 mM of [21-3H]-17a-hydroxypregnenolone and the Km and
Vmax values were determined at the optimum conditions. The
optimum conditions were microsomal protein content of 300 mg
protein per incubation, a substrate concentration of 0.48 mM, an
incubation time of 1 h and a pH of 7.4. The IC50 values for
inhibitors were calculated using linear regression analysis and the
plot of log of enzyme activity against log of inhibitor concentra-
tion. The Ki values were also determined at the same reaction
conditions with addition of appropriate concentrations of
inhibitors.  Ki values were calculated from a graph of the slopes of
the Lineweaver–Burke plots versus L-39 concentration using the
equation of the regression lines. The experiments were performed
in duplicate and repeated at least twice (i.e. n ³ 3).
5a-Reductase assay
The effects of novel compounds on human prostatic 5a-reductase
activity were evaluated as previously described (Li et al, 1992)
with some modifications. Ethanolic solutions of [1,2,6,7-3H]T
(600 000 dpm), cold T (4.8 ng), indicated inhibitors (0–200 nM)
and propylene glycol (10 ml) were added to duplicate sample
tubes. The control incubations were prepared without the addition
of the indicated inhibitors. The ethanol was evaporated to dryness
under a gentle stream of air. The samples were reconstituted in
phosphate buffer (0.1 M, pH 7.4, 400 ml) containing DTT (78 mM)
and the NADPH generating system (NADP, 6.5 mM; glucose-6-
phosphate, 71 mM; glucose-6-phosphate dehydrogenase, 2.5 IU, in
100 ml of phosphate buffer) was added to each tube. The tubes
were pre-incubated at 37°C for 15 min. The enzymatic reactions
were initiated by addition of human BPH microsomes (about 180
mg of microsomal protein in 500 ml of phosphate buffer) in a total
volume of 1.01 ml. The incubations were performed for 10 min
under oxygen in a shaking water bath at 37°C. The incubations
were terminated by placing the sample tubes on ice. [4-14C]-DHT
(3000 dpm) and cold DHT (50 mg) were added to each tube as an
internal standard and visualization marker respectively. These
additions were immediately followed by ether (1 ml). The steroids
were extracted with ether (3 ´ 1 ml), separated by TLC (chloro-
form:ether, 80:20) and visualized by exposure to iodine vapour.
The TLC spot corresponding to DHT was scraped, extracted with
ether and analysed for 3H and 14C using a liquid scintillation
counter. The percentage conversion of [1,2,6,7-3H]T to [1,2,6,7-
3H]DHT was calculated and used to determine 5a-reductase
activity. The reaction conditions were optimized with T (0–60 nM)
and the Km and Vmax values were estimated at the optimum condi-
tions. The optimum conditions were microsomal protein content of
180 mg protein per incubation, a substrate concentration of 40 nM,
an incubation time of 10 min and a pH of 7.4. The IC50 values were
determined from log-log plots of 5a-reductase activity against
four different concentrations of the inhibitor. The Ki values were
also determined at the same reaction conditions with addition of
appropriate concentrations of inhibitors. Ki values were calculated
from a graph of the slopes from the Lineweaver–Burke plots
versus L-39 concentration using the equation of the regression
line. The experiments were performed in duplicate and repeated at
least twice (i.e. n ³ 3).
Human PC-82 prostate cancer xenograft model
Male athymic Ncr-nu mice (~20 g) obtained from NCI (Frederick,
MD, USA) were maintained under sterile conditions in a
controlled environment of about 25°C, 50% relative humidity and
12 h of light and 12 h of dark cycles and allowed free access to
food and water. The experiments were performed in accordance
with guidelines approved by the Veterinary Resources Unit of the
University of Maryland School of Medicine, Baltimore. PC-82
tumour was originally kindly provided by Dr John Isaacs (John
Hopkins University). The PC-82 tumour (1000 mg) was minced in
pieces of 1–2 mm3, suspended in Matrigel (10 ml) and an aliquot
(0.1 ml) transplanted with a Trocar needle (18 gauge) into both
right and left flanks of 5–6 weeks old male athymic Ncr-nu mice.
The tumour volumes in each mouse were determined weekly using
calipers and allowed to reach 300 mm3 before treatment. Tumour
volumes were calculated using the following formula: tumour
volume = 0.5236 ´ r1
2 ´ r2 (r1 < r2), where r1 and r2 are radius
measurements from tumours. The animals were randomized into
treatment groups of 6–8 and administered vehicle (control),
flutamide and L-39. The compounds (10 mg ml–1) were dissolved
in 40% aqueous b-cyclodextrin and administered subcutaneously,
on the rear dorsal area of the animal, at a dose level of 50 mg kg–1
(~100 ml of drug formulation) daily for 28 consecutive days. A
group of mice (6–8) was castrated and injected with the vehicle
alone for 28 days. The animals were weighed and tumour volumes
measured weekly. The mice were sacrified at the end of the treat-
ment period (1–2 h after the last administered dose) and tumours
harvested. The tumours were cleaned, weighed and stored at
–70°C until analysis. Blood samples were also collected,
centrifuged to obtain serum and stored at –70°C until required.
Testosterone RIA
Serum and tumour tissues obtained from individual male mice
were thawed and homogenized in phosphate buffer (pH 7.4, 0.1
M). The homogenates were centrifuged at 2000 g for 20 min.
Serum (50 ml) and aliquots (50 ml) of the tissue supernatant were
used to determine T concentration as described in the 125I-T assay
kit supplied by DSL Inc. Radioactivity was measured using a
Packard Cobra II gamma counter.
DHT RIA
Serum and tumour tissues obtained from individual male mice
were thawed and homogenized in phosphate buffer (pH 7.4, 0.1
M). Serum (0.4 ml) and aliquots (0.4 ml) of the tumour supernatant
were extracted with 4 ml of hexane:ethanol (98:2) mixture. The
extracts were dried under a gentle stream of air, dissolved in
sample diluent and used for the determination of DHT concentra-
tions as described in the 125I-DHT assay kit. Radioactivity was
measured using a Packard Cobra II gamma counter.
PSA ELISA
Serum and tumour tissues obtained from individual mice were
thawed and homogenized in phosphate buffer (pH 7.4, 0.1 M). The
homogenates were centrifuged at 2000 g for 20 min. Serum andEffects of L-39 in vitro and in vivo 77
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aliquots of the tissue supernatant were diluted 1:10 in phosphate
buffer (pH 7.4, 0.1 M) and 25 ml used for the determination of
PSA concentrations as described in the PSA enzyme-linked
immunosorbent assay (ELISA) kit supplied by DSL Inc. The
absorbance was measured at 450 nm using a Dynatech MRX plate
reader.
Pharmacokinetic studies
Male Balb/c mice (8–10 weeks old) obtained from NCI (Frederick,
MD, USA) were maintained in a controlled environment of about
25°C, 50% relative humidity and 12 h of light and 12 h of dark
cycles and allowed free access to food and water. L-39 and
flutamide were formulated in 40% b-cyclodextrin in water and a
single subcutaneous or intravenous bolus dose was given to mice.
The animals were sacrificed at various times up to 24 h after drug
administration and blood was obtained by cardiac puncture under
light fluothane (Ayerst, New York, NY, USA) anaesthesia.
HPLC analysis
The high-performance liquid chromatographic (HPLC) system
consisted of a Waters® solvent delivery system, Waters 600
controller (Milford, MA, USA) coupled to Waters® 717plus
autosampler and a Water® 996 photodiode array detector operated
at 254 nm. Chromatographic separation and quantitation of L-39
and the internal standard, L-38, was achieved by reversed phase
HPLC on a Water® Novapak® C18 column (3.9 ´ 150 mm)
protected by a Waters® guard cartridge packed with pellicular
C18. The mobile phase composition was water/methanol/
acetonitrile/acetic acid (25:50:25:0.0001, v/v) and was pumped at
a flow rate of 1.0 ml min–1. The HPLC analysis was performed at
ambient temperature and data acquisition and management was
achieved with a Waters® millennium chromatography manager.
Sample preparation
L-39 and its D5 hydroxy derivative, L-38, were made up to 1 mg
ml–1 in ethanol and stored in the fridge (4°C) until required. From
these stock solutions, dilutions of 1, 10 and 100 mg ml–1 in ethanol
were prepared for use in construction of calibration curves. For
sample preparation, test-tubes containing plasma (250 ml), L-39
and the internal standard, L-38 (10 mg ml–1, 6.25 ml), were
extracted with diethyl ether (2 ´ 2 ml) using a vortex mixer for
1 min and centrifugation at 1500 g for 5 min. The organic layers
were evaporated to dryness under a gentle stream of air. The
extracts were reconstituted in acetonitrile (250 ml) and loaded into
a solid phase Sep-Pak 1cc C18 cartridge (Waters, Milford, MA,
USA) pre-washed with methanol (1 ml) for further purification.
The cartridge was then eluted with acetonitrile (250 ml), the eluate
evaporated to dryness and the residue reconstituted in mobile
phase (50 ml) and filtered using 0.2 mm teflon filters for HPLC
analysis.
Calibration curves and HPLC assay validation
The calibration curves for L-39 were constructed by spiking
varying amounts of L-39 (0–1 or 0–10 mg ml–1 ranges) and the
internal standard, L-38 (6.25 ml of 10 mg ml–1 or 6.25 ml of
100 mg ml–1 respectively) into extraction tubes containing blood
(0.25 ml) from untreated animals. The calibration samples were
taken through the extraction procedure as described above. An
aliquot of the reconstituted extract (10 ml) was injected onto the
HPLC column and the ratio of the peak area for L-39 to that of the
internal standard (L-38) were plotted against concentrations of
L-39. The analytical procedure was validated by determining the
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Figure 2 Inhibition of human testicular microsomal 17a-hydroxylase/C17,20-lyase by L-39. (A) Lineweaver–Burk plot of enzyme activities at various substrate
and inhibitor concentrations, (B) slopes of each reciprocal plot against L-39 concentration. Human testicular microsomes were prepared and
17a-hydroxylase/C17,20-lyase activity determined as described in Materials and Methods. The Km and Vmax values for 17a-hydroxylase/C17,20-lyase, under the
optimum incubation conditions were 0.48 mM and 40 pmole mg–1 protein min–1. Each point is the mean of duplicate determination of at least three separate
experiments. OH-P = 17a-hydroxypregnenolone. The standard deviations (not shown) were 5–8% of mean values. r ³ 0.99578 IP Nnane et al
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precision and accuracy of the method. The precision and accuracy
of the assay was determined by spiking known concentrations of
L-39 into sample tubes containing control plasma and taken
through the extraction procedure. The study was repeated on three
separate occasions and the coefficient of variation (CV), a measure
of precision, and the mean percentage difference, MD(%), a
measure of accuracy, were calculated.
Statistical analysis
Non-compartmental pharmacokinetic calculations were performed
using WinNonlin (Scientific consulting Inc.) One-way analysis of
variance (ANOVA) on SigmaStat for Windows version 1.0 was
used to compare different treatment groups at the 95% confidence
level. The Bonferroni post-hoc test was used for determination
of significance. A P-value of less than 0.05 was considered as
statistically significant.
RESULTS
The  Km and  Vmax values for 17a-hydroxylase/C17,20-lyase were
480 nM and 40 pmole mg–1 protein min–1 respectively, and the
reaction was linear with time for up to 1 h of incubation. L-39
showed potent and non-competitive inhibition of human testicular
microsomal 17a-hydroxylase/C17,20-lyase with an IC50 value of
59 nM and Ki of 22 nM (Figure 2). In comparison, ketoconazole, a
known competitive inhibitor of 17a-hydroxylase/C17,20-lyase, had
an IC50 value of 78 nM and Ki of 38 nM. L-39 also showed potent
and competitive inhibition of 5a-reductase in human prostatic
microsomes with IC50 and Ki values of 33 and 28 nM respectively
(Figure 3). In comparison, finasteride, a clinically available
inhibitor of 5a-reductase had an IC50 value of 33 nM and Ki of
36 nM. The Km and Vmax values for 5a-reductase were 40 nM and
2 pmole mg–1 protein min–1 respectively, and the reaction was
linear with time for up to 20 min of incubation.
Administration of L-39 (50 mg kg–1 daily, subcutaneously, for
28 days) to male athymic mice bearing PC-82 tumours signifi-
cantly reduced tumour volumes and weights compared to controls
(Figure 4). The volume of PC-82 prostate cancer xenografts in
athymic male nude mice increased by twofold over 28 days in the
control group. In comparison, the percentage increase in tumour
volume in mice treated with L-39 over 28 days was 1.25-fold.
L-39 also significantly diminished PC-82 tumour weights by 70%
(Figure 4). The potency of L-39 was similar to that of flutamide in
reducing the growth of human PC82 prostate tumour xenografts in
nude mice. Gross examination of vital organs such as the liver,
kidney and heart and the adrenal gland did not reveal toxicity.
Furthermore, the weight of these organs and the body weight of the
animals did not change significantly following treatment with L-
39 (50 mg kg–1). Data from other studies in our laboratory show
that maximum suppression of serum testosterone and DHT is
achieved by the 50 mg kg–1 dose of L-39. Hence, the 50 mg kg–1
dose was used in the tumour studies since increasing the dose
further did not result in a proportional decrease in serum androgen
levels. Furthermore, the 50 mg kg–1 dose was used in the tumour
studies because no difference in the plasma concentrations of L-39
was seen between the 50 and 100 mg kg–1 dose in the pharmaco-
kinetic studies (Figure 5).
L-39 significantly (P < 0.05) reduced T and DHT concentra-
tions in PC-82 tumour xenografts by 64% and 94% respectively,
although it failed to alter serum androgen levels to any significant
extent. L-39 also reduced (P < 0.01) serum and tumour PSA levels
by 80% and 50% respectively, and to about the same extent as
castration and flutamide treatment in mice bearing human prostate
cancer xenografts (Figure 6).
On reversed phase HPLC, L-39 was well resolved from the
internal standard (L-38) and other endogenous compounds in
mouse plasma (Figure 7). The calibration curves derived for L-39
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Figure 3 Inhibition of human prostatic microsomal 5a-reductase by L-39. (A) Lineweaver–Burk plot of enzyme activity at various substrate and inhibitor
concentrations, (B) Slopes of each reciprocal plot against L-39 concentration. Human prostatic microsomes were prepared and 5a-reductase activity
determined as described in Materials and Methods. The Km and Vmax values for 5a-reductase, under the optimum incubation conditions were 40 nM and
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were linear and reproducible (data not shown) and the inter- and
intra-assay variability was less than 10%. The limit of detection
for L-39 in mouse plasma was 0.05 mg ml–1. The HPLC assay was
validated and used to monitor L-39 concentrations in mice plasma.
The typical mean plasma concentration–time profiles of L-39 after
administration of a single bolus dose of 50 mg kg–1, intravenously
or subcutaneously, to male mice are shown in Figure 5. Following
intravenous administration, the plasma concentration of L-39
declined exponentially with a mean half-life of 0.66 h and a
terminal elimination rate constant of 1.052 h–1. L-39 was rapidly
cleared (total clearance of 3.5 l h–1 kg–1) from the systemic circula-
tion and was not detectable 4 h after administration. The calcu-
lated non-compartmental pharmacokinetic parameters based on
the plasma concentration profile following intravenous adminis-
tration of L-39 are shown on Table 1. L-39 was detected in mice
plasma from 5 min to 6 h following subcutaneous administration
of a 50 mg kg–1 dose. The blood levels of L-39 peaked at about
0.75 h and then declined exponentially (Figure 5) with a mean
half-life of 1.51 h and a terminal elimination rate constant of
0.46 per h. The bioavailability following subcutaneous administra-
tion of L-39 (50 mg kg–1) was 28.5%. The calculated non-
compartmental pharmacokinetic parameters based on the plasma
concentration profile following subcutaneous administration of
L-39 are shown on Table 1. The terminal slope of the plasma
concentration-time profile of L-39 following subcutaneous admin-
istration is shallower compared to the terminal slope following
intravenous dosing. Thus, the pharmacokinetic study indicates that
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Figure 5 Pharmacokinetics profile of L-39 following administration of a
single subcutaneous or intravenous bolus dose to male mice. Male Balb/c
mice (~20 g) were injected with L-39 (50 and 100 mg kg–1) as a single bolus
dose and blood collected at predetermined time points. The samples were
analysed as described in Materials and Methods. Each data point represents
the mean of plasma concentrations obtained from at least three mice. The
standard deviations (not shown) were ± 3–7% of the mean values
Table 1 Pharmacokinetic parameters of L-39 in mice following a single
intravenous or subcutaneous bolus dose
Parameter Subcutaneous
Intravenous
50 mg kg–1 100 mg kg–1 50 mg kg–1
Kel (h–1) 0.46 ± 0.02 0.53 ± 0.03 1.05 ± 0.05
T1/2> (h) 1.51 ± 0.08 1.31 ± 0.06 0.66 ± 0.04
AUC0-∞mg ml–1.h–1) 4.09 ± 0.16 4.04 ± 0.20 14.41 ± 0.56
CI (l h–1 kg–1) 12.24 ± 0.48 24.78 ± 1.0 3.47 ± 0.14
Vd (l kg–1) 26.73 ± 1.04 46.80 ± 1.84 3.30 ± 0.13
MTR (h) 2.52 ± 0.11 2.41 ± 0.10 1.15 ± 0.05
Tmax (h) 0.75 ± 0.0 1.0 ± 0.0 –
Cmax (mg ml–1) 1.42 ± 0.05 1.30 ± 0.04 –
Male mice (25 ± 5 g) were injected with L-39 (50 or 100 mg kg–1, s.c. or
50 mg kg–1 i.v). The animals were sacrificed and blood collected at
predetermined time points. plasma concentrations of L-39 were determined
by HPLC, as described in Materials and Methods. Values represent the
means ± standard deviations from at least three mice.80 IP Nnane et al
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L-39 persists in the blood longer when administered subcuta-
neously. When a higher dose of L-39 (100 mg kg–1) was adminis-
tered subcutaneously to male mice, the plasma concentration
versus time curve was almost superimposable on the plasma
concentration versus time curve for the 50 mg kg–1 following
subcutaneous administration of L-39. Hence, the area under the
plasma concentration–time profile did not change significantly
after subcutaneous administration of the higher dose (Table 1).
However, the volume of distribution and the total clearance were
increased significantly at the higher dose.
DISCUSSION
17a-hydroxylase/C17,20-lyase catalyses the early step in the biosyn-
thesis of T and other androgens in both the testes and the adrenal
glands, while 5a-reductase converts T to DHT in the prostate
gland (Saunders, 1963). Both T and its metabolite, DHT, promote
prostatic growth and cancer. Thus, inhibition of both enzymes
would be expected to result in diminished levels of circulating T
and DHT and therefore serve as a useful strategy for developing
new treatments for prostate cancer (Nnane et al, 1998, 1999).
Several inhibitors of 17a-hydroxylase/C17,20-lyase and/or 5a-
reductase have been described previously, however, they have a
number of limitations. Ketoconazole, currently used in the treat-
ment of prostate cancer, is an inhibitor of several P450 enzymes
including 17a-hydroxylase/C17,20-lyase (Small et al, 1997), and
causes side-effects such as nausea, dry skin, asthenia, etc.
(Trachtenberg, 1984). Finasteride, an inhibitor of 5a-reductase,
induces accumulation of T (Peters and Sorkin, 1993) and has no
activity against 17a-hydroxylase/C17,20-lyase (Nnane et al, 1998).
L-39 is a dual inhibitor of 17a-hydroxylase/C17,20-lyase and
5a-reductase. L-39 showed non-competitive inhibition and prob-
ably binds strongly to the apoprotein of 17a-hydroxylase/C17,20-
lyase (Figure 2). L-39 was a potent competitive inhibitor of
5a-reductase. The observed anti-tumour effects of L-39 are there-
fore due to its potent inhibition of androgen synthesis, at least in
part. L-39 (5 mM) has also been shown to manifest anti-androgenic
activity in cultures of human prostate cancer cell lines (LNCaP) by
preventing the labelled synthetic androgen R1881 (5 nM) from
binding to the androgen receptors (Long et al, 1999). The inter-
action of L-39 with the androgen receptor together with its potent
inhibition of androgen synthesis makes L-39 a promising lead
compound for the treatment of prostate cancer.
Furthermore, L-39 was effective in vivo in reducing tumour
volumes and weights and PSA and androgen levels in tumour
tissues. These effects were produced without a significant change
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the weights of vital organs and the body weight of the animals
following treatment with L-39 (50 mg kg–1), an indication that the
compound is well tolerated by the animals.
Surgical castration is the traditional approach to lower androgen
levels in vivo and was used in this investigation as the standard for
comparison. This novel steroid was as effective as castration and
flutamide in reducing androgen concentration and PSA levels in
tumour tissues. Flutamide, an anti-androgen, is currently used
clinically in combination with LHRH analogue, leuprolide
(Crawford et al, 1989). However, the duration of its effect is often
limited by the development of androgen receptor mutants that
respond to flutamide as an agonist. Tumour growth and weight are
regulated by both T and DHT, albeit to a greater extent by the latter
(Wilson, 1996). Thus, the significant reduction in the levels of
androgens by L-39 may explain the corresponding reduction in
tumour volume and weight observed after treatment of nude mice
bearing PC-82 tumors with L-39. The serum marker, PSA, has
been used to determine the status of prostate cancer in patients and
is a valid end point for assessing progression of the disease
(Roach, 1996). Our novel androstene derivative, L-39, was effec-
tive in lowering PSA levels (P < 0.001) in mice bearing human
PC-82 tumours and its effectiveness was similar to that of castra-
tion (P > 0.05). Other studies in our laboratory indicate that L-39
inhibits proliferation LNCaP human prostate cancer cells in
culture and is effective at slowing LNCaP human prostatic cells
grown in male SCID mice as tumours (Long et al, 1999). This
finding suggests that L-39 may also be effective in treating
tumours with the mutated androgen receptor.
Our results indicate that although L-39 is a potent inhibitor of
androgen synthesis in vitro and is effective in reducing serum and
tumour androgen concentrations, its effectiveness in vivo on T
levels is weaker than that of castration. The half-life of L-39 was
about 1.51 h after subcutaneous administration. The relatively
short half-life of the compound may explain its efficacy in vivo
since it was less than expected based on its in vitro potency. It may
be necessary to administer L-39 more frequently or increase its
bioavailability in order to increase efficacy in vivo. Although the
in vivo activity of L-39 was less than expected, the observed anti-
tumour effect suggests that the initial concentrations of L-39 in
circulation may be sufficiently high for the compound to irre-
versibly bind and saturate the 17a-hydroxylase/C17,20-lyase. In
fact, other steroidal compounds with a 16–17 double bond have
been shown to be irreversible inhibitors of 17a-hydroxylase/C17,20-
lyase (Jarman et al, 1990). The pharmacokinetics study indicate
that L-39 persists in the blood slightly longer when administered
subcutaneously. This persistence may be due to slower release of
L-39 into the systemic circulation from the subcutaneous depot
and may be a more useful method of administration for achieving
levels that inhibit the enzyme and bind androgen receptors in the
tumour. The relatively low bioavailability (28.5%) of the
compound may also be limiting its efficacy in vivo. The area under
the curve did not increase proportionately with an increase in the
dose of L-39 following subcutaneous administration. It would
appear, therefore, that L-39 exhibits non-linear pharmacokinetics.
This observation suggests that the processes of uptake, distribution
and metabolism of L-39 are saturable and that the doses used are
sufficiently high to cause saturation of these processes. Initial
observations in our laboratory indicate that L-39 is metabolized to
a more polar metabolite in mice although the metabolite has not
yet been characterized. Moreover, L-39 is poorly soluble in water
and was formulated in 40% aqueous b-cyclodextrin. Although a
homogeneous solution was obtained with 40% aqueous b-
cyclodextrin, L-39 may precipitate at the site of injection. This
may affect the rate and extent of L-39 that is systemically available
and that may explain, at least in part, the observed non-linear
kinetics of L-39. The relatively large volume of distribution
suggests that L-39 may be extensively bound to plasma proteins or
is distributed extensively within the extravascular tissues. Studies
on the uptake and distribution of the compound into the testis and
tumours and on protein binding are in progress. Studies are also in
progress to improve the formulation of L-39 such that adequate
levels of the drug are maintained in the systemic circulation for a
longer period of time in order to increase it efficacy in vivo.
In conclusion, the findings in this investigation indicate that
L-39 is a potent inhibitor of androgen synthesis and is also effec-
tive in reducing the growth of human PC-82 tumours in nude mice.
Recent studies in our laboratory have also shown that L-39 mani-
fests anti-androgenic activity in vitro and that it blocked the
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mutated androgen receptor in LNCaP cells. Thus, the compound
was more effective than flutamide in mice with LNCaP tumours
(Long et al, 1999). Although inhibition of androgen synthesis
appear to be the primary mode of action of L-39, the overall anti-
tumour effect, due to its other mechanisms of action, may be of
benefit in treating prostate cancer. In fact, the ability of L-39 to
interact with the androgen receptor may also contribute signi-
ficantly to the observed anti-tumour activity in vivo. Although
improvements in the formulation and pharmacokinetic profile are
necessary, L-39 is a promising lead compound for the treatment of
hormone-dependent cancer of the prostate.
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